Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

杜瓦卢马布 医学 内科学 肿瘤科 子群分析 析因分析 放化疗 阶段(地层学) 养生 置信区间 癌症 总体生存率 免疫疗法 无容量 生物 古生物学
作者
Jarushka Naidoo,Scott Antonia,Yi−Long Wu,Byoung Chul Cho,Piruntha Thiyagarajah,Helen Mann,Michael Newton,C. Faivre‐Finn
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (5): 657-663 被引量:56
标识
DOI:10.1016/j.jtho.2023.02.009
摘要

Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the phase 3 placebo-controlled PACIFIC study (NCT02125461). Nevertheless, the benefit of immunotherapy in patients with stage III EGFR-mutant (EGFRm) NSCLC is not well characterized. Here, we report a post hoc exploratory efficacy and safety analysis from a subgroup of patients with EGFRm NSCLC from the PACIFIC.Patients with stage III unresectable NSCLC and no progression after more than or equal to two cycles of platinum-based concurrent chemoradiotherapy were randomized (2:1) to receive durvalumab (10 mg/kg intravenously every 2 weeks [wk], for up to 1 y) or placebo; stratified by age, sex, and smoking history. Enrollment was not restricted by oncogenic driver gene mutation status or programmed death-ligand 1 expression. Patients with NSCLC with an EGFR mutation, determined by local testing only, were included in this subgroup analysis. The primary end points were progression-free survival (PFS; assessed by blinded independent central review) and overall survival (OS). Secondary end points included objective response rate and safety. Statistical analyses for the subgroup of patients with EGFRm NSCLC were post hoc and considered exploratory.Of 713 patients randomized, 35 had locally confirmed EGFRm NSCLC (durvalumab, n = 24; placebo, n = 11). At data cutoff (January 11, 2021), median duration of follow-up for survival was 42.7 months (range: 3.7-74.3 mo) for all randomized patients in the subgroup. Median PFS was 11.2 months (95% confidence interval [CI]: 7.3-20.7) with durvalumab versus 10.9 months (95% CI: 1.9-not evaluable [NE]) with placebo; hazard ratio = 0.91 (95% CI: 0.39-2.13). Median OS was 46.8 months (95% CI: 29.9-NE) with durvalumab versus 43.0 months (95% CI: 14.9-NE) with placebo; hazard ratio = 1.02 (95% CI: 0.39-2.63). The safety profile of durvalumab was generally consistent with the overall population and known profile for durvalumab.PFS and OS outcomes with durvalumab were similar to placebo for patients with EGFRm tumors, with wide CIs. These data should be interpreted with caution owing to small patient numbers and lack of a prospective study that evaluates clinical outcomes by tumor biomarker status. Further research to determine the optimal treatment for unresectable stage III EGFRm NSCLC is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zq完成签到,获得积分20
刚刚
HY完成签到,获得积分10
1秒前
不再挨训完成签到 ,获得积分10
2秒前
学术乞丐完成签到,获得积分20
4秒前
咖啡博士完成签到,获得积分10
5秒前
韭黄发布了新的文献求助10
6秒前
Singularity完成签到,获得积分0
8秒前
JamesPei应助zq采纳,获得10
9秒前
所所应助韭黄采纳,获得10
13秒前
江霭完成签到,获得积分10
16秒前
鲤鱼青槐完成签到,获得积分10
25秒前
量子星尘发布了新的文献求助10
26秒前
29秒前
缥缈的冰旋完成签到,获得积分10
29秒前
35秒前
36秒前
ailemonmint完成签到 ,获得积分10
36秒前
37秒前
玉ER完成签到,获得积分10
38秒前
39秒前
四十四次日落完成签到 ,获得积分10
39秒前
科研通AI2S应助羊二呆采纳,获得10
39秒前
英吉利25发布了新的文献求助10
41秒前
42秒前
水晶茶杯发布了新的文献求助10
43秒前
欢欢完成签到,获得积分10
44秒前
茯苓完成签到 ,获得积分10
46秒前
小鱼发布了新的文献求助10
47秒前
香香丿完成签到 ,获得积分10
47秒前
48秒前
万能图书馆应助zz123采纳,获得10
48秒前
杜康完成签到,获得积分10
48秒前
Cheung2121发布了新的文献求助10
48秒前
医学小王完成签到 ,获得积分10
49秒前
51秒前
刘涵完成签到 ,获得积分10
52秒前
帅气的沧海完成签到 ,获得积分10
53秒前
辣辣辣辣辣辣完成签到 ,获得积分10
56秒前
57秒前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022